JP2005523882A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523882A5
JP2005523882A5 JP2003535713A JP2003535713A JP2005523882A5 JP 2005523882 A5 JP2005523882 A5 JP 2005523882A5 JP 2003535713 A JP2003535713 A JP 2003535713A JP 2003535713 A JP2003535713 A JP 2003535713A JP 2005523882 A5 JP2005523882 A5 JP 2005523882A5
Authority
JP
Japan
Prior art keywords
protein
weight percent
pharmaceutical composition
mixture
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003535713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/032872 external-priority patent/WO2003032907A2/en
Publication of JP2005523882A publication Critical patent/JP2005523882A/ja
Publication of JP2005523882A5 publication Critical patent/JP2005523882A5/ja
Pending legal-status Critical Current

Links

JP2003535713A 2001-10-16 2002-10-16 高濃度タンパク質製剤および製造の方法 Pending JP2005523882A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33021301P 2001-10-16 2001-10-16
PCT/US2002/032872 WO2003032907A2 (en) 2001-10-16 2002-10-16 High-concentration protein formulations and method of manufacture

Publications (2)

Publication Number Publication Date
JP2005523882A JP2005523882A (ja) 2005-08-11
JP2005523882A5 true JP2005523882A5 (https=) 2006-01-05

Family

ID=23288780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535713A Pending JP2005523882A (ja) 2001-10-16 2002-10-16 高濃度タンパク質製剤および製造の方法

Country Status (8)

Country Link
US (1) US8372798B2 (https=)
EP (1) EP1441748A4 (https=)
JP (1) JP2005523882A (https=)
CN (1) CN1604788B (https=)
AU (1) AU2002335815A1 (https=)
BR (1) BR0213298A (https=)
MX (1) MXPA04003640A (https=)
WO (1) WO2003032907A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
JP2007538048A (ja) * 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
EP2044934A1 (en) * 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
KR20200032244A (ko) * 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
IL325155A (en) 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
WO2021042090A2 (en) * 2020-11-27 2021-03-04 Schott Ag System for long time storage of pharmaceutical compositions at low temperatures

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
PT682524E (pt) * 1993-02-02 2002-03-28 Xoma Technology Ltd Composicoes farmaceuticas que contem a proteina bactericida indutora da permeabilidade e um agente tensioactivo
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
BR0111948A (pt) * 2000-06-26 2004-08-24 Rxkinetix Inc Composição para entrega de fator de crescimento hematopoiético
US6613907B2 (en) * 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms

Similar Documents

Publication Publication Date Title
JP2005523882A5 (https=)
KR100597500B1 (ko) 안정한 인슐린 제제
AU632634B2 (en) Drug delivery system, method for preparing the same, and use thereof
JP6892494B2 (ja) パラセタモール及びイブプロフェンを含む水性配合物
JP2012051891A (ja) 成長ホルモン製剤
NO316104B1 (no) Blanding for vedvarende frigjöring av humant veksthormon
US8372798B2 (en) High-concentration protein formulations and method of manufacture
NO332937B1 (no) Frysetorket pantoprazol-preparat og fremgangs-mate ved fremstilling av det samme samt pantoprazol-injeksjonspreparat» slik at den omfatter en omtale av de ulike aspektene ved oppfinnelsen
JP3723857B2 (ja) ヒト成長ホルモン含有水性医薬組成物
US11298399B2 (en) Carbetocin drug product and process for preparing same
WO2002067989A1 (en) Crystallisation-resistant aqueous growth hormone formulations
EP2089001A2 (en) High protein concentration formulations containing mannitol
JP2009502972A (ja) タンパク質凝集を抑制する製剤
Gao et al. Study of a Pingyangmycin delivery system: Zein/Zein–SAIB in situ gels
US9114127B2 (en) Biologic devices for hemostasis
WO2025223401A1 (zh) 一种壳聚糖基温敏型内镜黏膜下注射液及其制备方法和应用
US20080233196A1 (en) Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles
CN105616343A (zh) 一种硫辛酸注射液及其制备方法
CN103157096B (zh) 一种特立帕肽缓释微球及其制备方法
SU1072789A3 (ru) Способ получени соли стероида дл парентерального введени
CN102421426A (zh) 肠胃外给药的对乙酰氨基酚
JP2011137048A (ja) 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス
CN106963729A (zh) 一种用于预防手术出血的药物制剂及其制备方法
CN105535942B (zh) 一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
CN110200905B (zh) 一种盐酸氨溴索组合物及其注射液与应用